Congrats Mark...
I try to follow PCYC but don't own...
I found this on their board today....
LARCHMONT, N.Y.--(BUSINESS WIRE)--March 2, 2004--Biotechnology companies will continue to build on the upbeat economy and positive investor sentiment that began last year as they seek to fund their operations in 2004, according to Genetic Engineering News (GEN; www.genengnews.com). Enjoying strong underlying fundamentals and a bullish but selective investor attitude, biofirms are poised for growth this year, reports the March 1 issue of GEN, which features the publication's Annual Wall Street Analysts' Roundup.
"Biotech companies are taking advantage of a reinvigorated investor attitude toward the industry as they move their products through clinical trials and toward the marketplace," says John Sterling, Editor-in-Chief of GEN. "The large turnouts at the recent J.P. Morgan Healthcare Conference in San Francisco and the BIO CEO & Investor Conference in New York give ample testament to the renewed enthusiasm in biotech."
Based on expanded valuation metrics in 2003, Standard & Poor's believes there is additional upside potential for biotech in 2004, notes Frank Dilorenzo, the S&P analyst who took part in GEN's Wall Street Roundup. Kate Winkler, Ph.D., VP of equity research at Merriman Curhan Ford & Co., thinks there will be renewed interest in large pharma companies this year while Thomas Dietz, Ph.D., and Greg Wade, Ph.D., analysts at Pacific Growth Equities, see a strong theme of "selectivity" toward biotech throughout 2004.
Nola Masterson, managing partner, Science Futures; Patrick N.J. Schnegelsberg-Pettersson, analyst, Mehta Parthers; and John F. Wong, Ph.D., chairman, SciFin, also presented their perspectives on biotech in the GEN Wall Street feature.
Among the analysts' top biotech stock picks for 2004 are Amgen (NASDAQ:AMGN), Biogen Idec (NASDAQ:BIIB), Genzyme (NASDAQ:GENZ), Gilead Sciences (NASDAQ:GILD), Genentech (NYSE:DNA), Esperion Therapeutics (NASDAQ:ESPR), ICOS (NASDAQ:ICOS), Millennium Pharmacuticals (NASDAQ:MLNM), Dendreon (NASDAQ:DNDN), ImClone Systems (NASDAQ:IMCL), Cytogen (NASDAQ:CYTO), Durect (NASDAQ:DRRX), Adolor (NASDAQ:ADLR), Alfacell (OTC:ACEL), Pharmacyclics (NASDAQ:PCYC), Pharmion (NASDAQ:PHRM), Celgene (NASDAQ:CELG), Vicuron Pharmaceuticals (NASDAQ:MICU), and Pain Therapeutics (NASDAQ:PTIE), among others.
Genetic Engineering News is published 21 times a year by Mary Ann Liebert, Inc. For a copy of the March 1 issue, please call 914-834-3100, ext. 623, or email: ebicovny@liebertpub.com.
bvg |
